# GoodRx Holdings Inc. (GDRX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $3.49, market value $1.2 billion.

## Valuation
- **P/E (trailing): 69.8×** (5-yr avg 73.2×, 3-yr avg 73.2×). GoodRx Holdings Inc. trades at 69.8× trailing earnings, close to its own five-year average of 73.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.08**. A PEG of 0.08 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.5×**. Each dollar of revenue is priced at 1.5×.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 8.7×**. Enterprise value is 8.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 16.6%** (5-yr avg 8.1%). Free cash flow equals 16.6% of the market value, above its five-year average of 8.1%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 1.4%**. The inverse of the P/E: 1.4% of the price is earned each year.

## Profitability
- **Operating margin: 9.5%**. 9.5% of revenue is left after running the business.
- **Net margin: 3.8%**. 3.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 4.9%**. 4.9% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 7.0%**. Return on all capital, debt included, is 7.0%.
- **Return on assets: 1.2%**. Each dollar of assets produces 1.2% of profit.

## Growth
- **Revenue growth (1 yr): 0.6%** (3-yr 1.3%/yr, 5-yr 7.7%/yr). Revenue grew 0.6% over the last year, against 7.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 125.0%**. Earnings per share rose 125.0%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 4.8%/yr**. Free cash flow has compounded at 4.8% a year over three years.

## Financial health
- **Debt to equity: 0.79**. Debt is 0.79 times equity, moderate leverage.
- **Net debt / EBITDA: 1.4×**. It would take 1.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.61** (quick 2.61). Current assets cover the next year's liabilities 2.61 times.
- **Altman Z-score: 2.63**. A Z-score of 2.63 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. GoodRx Holdings Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (12 analysts). 12 analysts cover GoodRx Holdings Inc.; the consensus is hold, with an average price target of $3.95 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 5.3%** (YTD 31.0%, 3-mo 12.3%). The shares are up 5.3% over twelve months including dividends.
- **From 52-week high: -10.3%** (97.2% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.34** (volatility 55%). Beta of 1.34 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GDRX · Page: https://foliofundamentals.com/stocks/gdrx

Not investment advice.